This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Y. Articles by Keep, R. F. Search for Related Content PubMed PubMed Citation Articles by Zhang, Y. Articles by Keep, R. F. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Transient Ischemic Attack

(Stroke. 2001;32:1378.)
© 2001 American Heart Association, Inc.

Original Contributions

Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System

Yun Zhang, PhD William M. Pardridge, MD

From the Department of Medicine, University of California at Los Angeles School of Medicine.

Background and Purpose—Neuroprotection with brain-derived neurotrophic factor (BDNF) requires direct injection into the brain owing to poor transport of the neurotrophin through the blood-brain barrier (BBB) in vivo. The present studies investigate whether BDNF alone or conjugated to a BBB drug targeting system is neuroprotective in focal, reversible brain ischemia after delayed intravenous administration at 60 or 120 minutes after middle cerebral arterial occlusion.

Methods—BDNF was conjugated to the OX26 murine monoclonal antibody to the rat transferrin receptor, which undergoes transport into brain from blood via the BBB transferrin receptor transcytosis system. After a 1-hour occlusion of the middle cerebral artery in nitrous oxide– ventilated animals with normal blood sugar, the brain was reperfused, and either BDNF or the BDNF/OX26 conjugate was administered as a single intravenous injection at a dose of 50 µg per rat.

Results—After the intravenous administration of unconjugated BDNF, there was no neuroprotection on the basis of analysis of brain at either 24 hours or 7 days after a 1-hour middle cerebral arterial occlusion. In contrast, there was a 68% and 70% reduction in cortical stroke volume at 24 hours and 7 days, respectively, after intravenous administration of 50 µg per rat of the BDNF conjugate (P<0.01). No effects on subcortical stroke volume were observed.

Conclusions—These studies demonstrate marked neuroprotection in focal, transient brain ischemia with a single, delayed intravenous injection of BDNF if the neurotrophin is conjugated to a BBB drug targeting system. The neuroprotection is long lasting and persists for at least 7 days after a 1-hour middle cerebral artery occlusion.

Editorial Comment

Richard F. Keep, PhD, Guest Editor

Crosby Neurological Laboratories, University of Michigan, Ann Arbor, Michigan, rkeep@med.umich.edu

This article has been cited by other articles:

				Z. M. Qian, H. Li, H. Sun, and K. Ho Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway Pharmacol. Rev., December 1, 2002; 54(4): 561 - 587. [Abstract] [Full Text] [PDF]

				B.-W. Song, H. V. Vinters, D. Wu, and W. M. Pardridge Enhanced Neuroprotective Effects of Basic Fibroblast Growth Factor in Regional Brain Ischemia after Conjugation to a Blood-Brain Barrier Delivery Vector J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 605 - 610. [Abstract] [Full Text] [PDF]

				F. Schlachetzki, T. Holscher, H. J. Koch, B. Draganski, A. May, G. Schuierer, and U. Bogdahn Observation on the Integrity of the Blood-Brain Barrier After Microbubble Destruction by Diagnostic Transcranial Color-Coded Sonography J. Ultrasound Med., April 1, 2002; 21(4): 419 - 429. [Abstract] [Full Text] [PDF]

				W. M. Pardridge Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier Arch Neurol, January 1, 2002; 59(1): 35 - 40. [Abstract] [Full Text] [PDF]